Inovio Reports Q3 2026 Financial Results and VOCERYQ Commercialization Roadmap
Inovio (INO) reported a net loss of $49.2 million ($0.50 per share) for the third quarter of 2026, largely driven by a $26.9 million non-cash fair value adjustment on warrant liabilities. Despite the loss, the company successfully raised $80.5 million through a public offering, extending its cash runway into late 2027. As of September 30, 2026, cash and short-term investments stood at $48.4 million, excluding recent equity proceeds. The company is pivoting toward the commercial launch of VOCERYQ for recurrent respiratory papillomatosis (RRP). Management expects product availability by late December 2026, with full field deployment across 20 territories scheduled for Q1 2027. Inovio aims to achieve payer coverage for 80% of U.S. patients within nine months of approval and is preparing a European regulatory submission before the end of 2026.
Tickers: $INO
Topics: cash runway commercial launch earnings report public offering